reportingrisk.com← the monitorSEC reporting failures, scored and checked against what happened next

Or browse all companies A–Z.

AIM ImmunoTech Inc.

AIM · NYSE

1 reporting failure in the last 12 months

Companies at this level ended the following year delisted, bankrupt, restated or silent 9.2% of the time, against 4.0% for companies with a clean record.

$6Mpublic float
2025-11-17most recent failure

Score over time

012202220232024202520262022-01-01 · score 12021-01-22 auditor change2026-01-01 · score 12025-11-17 filed late (10-Q) · accounts not ready2026-04-01 · score 12025-11-17 filed late (10-Q) · accounts not ready2026-07-01 · score 12025-11-17 filed late (10-Q) · accounts not ready2026-10-01 · score 12025-11-17 filed late (10-Q) · accounts not ready

Hover or tap a dot to see the filings behind that score.

Why they said they were late

The Registrant is unable to file its Quarterly Report on Form 10-Q for the period ended September 30, 2025, within the prescribed time due to delays in completing the required review. Additional time is needed for management to compile and verify the data to be included in the report. The Registrant expects to file within the permitted extension period. Robert Dickey IV 610 864-6470 (Name) (Area Code) (Telephone Number) PART IV — OTHER INFORMATION (1) Name and telephone number of person to contact in regard to this notification (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes ☒ No ☐ (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes ☒ No ☐ If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. See attached. 2 of 4 Aim ImmunoTech Inc. (Name of Registrant as Specified in Charter) has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized. Date November 17, 2025 By /s/ Robert Dickey IV Robert Dickey IV Chief Financial Officer INSTRUCTION: The Form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the Form shall be typed or printed beneath the signature

NT 10-Q, filed 2025-11-17 · accounts not ready

What it filed

2025-11-17filed late (10-Q)accounts not ready SEC →

The Registrant is unable to file its Quarterly Report on Form 10-Q for the period ended September 30, 2025, within the prescribed time due to delays in completing the required review. Additional time is needed for management to compile and verify the data to be included in the report. The Registrant expects to file within the permitted extension period. Robert Dickey IV 610 864-6470 (Name) (Area Code) (Telephone Number) PART IV — OTHER INFORMATION (1) Name and telephone number of person to contact in regard to this notification (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes ☒ No ☐ (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes ☒ No ☐ If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. See attached. 2 of 4 Aim ImmunoTech Inc. (Name of Registrant as Specified in Charter) has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized. Date November 17, 2025 By /s/ Robert Dickey IV Robert Dickey IV Chief Financial Officer INSTRUCTION: The Form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the Form shall be typed or printed beneath the signature

2021-01-22auditor changed or resigned SEC →

About this score

reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.

Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.

See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.

Every item above is a filing this company made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not investment advice

reportingrisk.com← back to the monitorAll companies A-Z · RSS · found an error? hello@reportingrisk.com